Covid alert

Despite the fact that European authorities assure that the continent is prepared, the wave of Covid from China is expected with fear. Although the World Health Organization (WHO) minimized the impact it could cause, European countries are on alert.

According to the WHO, supported by the European Center for Disease Control (ECDC), Covid infections in China are not expected to have a significant impact in Europe since the variants circulating in the Asian country have been eradicated on the continent.

For its part, in December China put an end to its anti-Covid policy, based on restrictions on mobility and severe confinements for its population. With its borders open, both to foreign visitors and abroad, tourists from the Asian giant have arrived in Europe and other countries.

That is why health security measures have been intensified, such as the insistence on negative tests for travelers. Especially since several European countries are dealing with collapsed healthcare systems for various reasons. Among them are understaffing, strikes, bed shortages, inability to handle the volume of emergencies youporn.

The most affected countries are France, whose hospitals are at maximum capacity and understaffed; Germany, in which health personnel are on leave due to Covid and other seasonal illnesses; Austria, which is dealing with drug shortages, and the UK, where emergency services are stretched thin.



Covid variant

The WHO insists that Europe is prepared for a possible rebound in infections, especially due to its high levels of vaccination. Despite this, the organization’s director for Europe, Hans Kluge, urged European countries to take proportional, non-discriminatory and science-based measures, since there are marked differences between the requirements for travelers from China and those who They come from the United States.

France and Germany request a negative Covid test from those coming from the Asian giant, while Spain demands either a negative test or a full vaccination certificate. This does not happen with those who travel from North America, despite the fact that a new variant has been detected there (XBB.1.5, which is more contagious).

“In December China put an end to its anti-Covid policy, based on restrictions on mobility and severe confinements for its population”

However, he insisted that the priority measure must be the use of the mask on long-haul flights. Likewise, Kluge assured that it would be advisable to extend its use in public transport and other high-risk places. Another of the measures that is insisted on is vaccination, and ventilation of closed spaces.

For his part, Public Health expert Rafael Bengoa insists that Europe cannot be trusted and must tighten controls on travelers. In an interview with Europa Press, he criticized China for ending its confinement policy without preparing the exit with vaccination.



Related Posts




Several countries in Europe, including the UK and Germany, have reported a significant increase in Covid-19 cases, in what is called the autumn wave. Lax public health measures, lack of knowledge about booster doses of the vaccine, as well as a perception of “false safety” could be contributing to the increase in transmission.

According to a joint official statement by the European Commission (EC) and the European Centre for Disease Prevention and Control (ECDC), although the pandemic is considered to have decreased in urgency compared to last year, humanity may soon face a new wave of infections tukif.

WHO officials said that among the variants circulating in Europe are the BA.4/5 sub-variants of Omicron, which dominated this northern summer and are still behind the majority of infections. However, new sub-variants of Omicron are being tracked.



Last week, the WHO said cases in the European Union reached 1.5 million, up 8% from the previous week. Hospitalisation figures have also been rising in several countries in the bloc, as well as in the UK, according to CNN.

The president of the German Hospital Association, Gerhard Gaß, said on Wednesday 12 October that the country’s hospitals were at capacity. He also reported that the number of beds occupied by positive patients had increased by 50 percent compared to last week.


According to the WHO, France already has an incidence of 800 cases per 100,000 population of coronavirus. On the other hand, for the week of 4 October, admissions for Covid-19 in Italy increased by almost 32% compared to the previous week, according to data from the independent scientific foundation Gimbe cited by CNN.



Now, while the European Parliament is investigating the Pfizer contracts, new vaccines adapted to the omicron variant have been launched on the European continent. These, which have been available since September, address the BA.1 and BA.4/5 sub-variants, alongside existing first generation vaccines. While in Great Britain, they are only approved for the BA.1 sub-variant.

The authorities in these countries have approved late booster doses for a select group of people, especially the elderly and people with compromised immune systems. However, confusion over choosing which vaccine to use, as well as a false sense of security, have been two obstacles to vaccination, according to experts in the field.


Martin McKee, a professor of European public health at the London School of Hygiene and Tropical Medicine, said that “the message that it’s all over, coupled with the lack of a major publicity campaign, is likely to reduce uptake (of the vaccine),” as quoted by CNN.

However, the WHO insists that prevention measures and vaccination, which is “our most effective tool”, must be maintained. The agency also urges other nations to make additional efforts to protect the most vulnerable segments of the population by distributing influenza and COVID-19 vaccines.



Related Posts



Centauro, the new variant of the covid that worries ( Pexel)

The year 2020 was a nightmare for many. Being locked up at home for so long left scars on our society and economy that even today, more than two years later, we are still trying to repair. Therefore, it is not surprising when panic appears before a potential new threat.

In the case of COVID-19, there have been numerous variants that have emerged since its first appearance. Beta, Delta and Omicron are some of the most striking. However, thanks to the timely appearance of vaccines and other factors, each of them has been controlled.

However, currently there have been cases of a new variant that is presumed to be much more dangerous than the previous ones: Centaur or “Centaurus”. Originally from India, where at least 20% of the cases known so far are registered, it has managed to spread to countries such as Canada, New Zealand and the United Kingdom at a worrying speed.



It is still early to assume that we know everything about this new variant. At the moment, there is hardly any information about its level of transmissibility or evasion, as well as the effect it may or may not have on the vaccines that the majority of the population currently has.

However, it is recommended to remain alert to the presence of:
• Strong headaches that occur continuously and for periods of acute without external explanation.
• Fever, cough and nasal congestion, as main alerts of airway blockage.
• Throat pain.
• General discomfort.



According to data provided by Soumya Swaminathan, chief scientist of the OMS, Centaur has 16 mutations noted with respect to previous variants. Two of them, G446S and R493Q, are the ones of greatest concern to the scientific community porno français, due to their potential ability to evade immunity from vaccines and previous infections.

However, this aspect is still under study and there is still not enough evidence to confirm it. This does not necessarily mean that we are safer. On the contrary. By not knowing the limits of this variant, acting on it is a gamble.



In order to keep the population safe, the Centers for Disease Control and Prevention (CDC) make the following recommendations:
• To start with, an additional dose of mRNA vaccine is recommended. In the first instance, this is of vital importance for people with weakened immune systems due to natural causes or compromised by external factors. According to the recommendation, it should be given at least 2 weeks after the second mRNA vaccine booster.
• Preventive health control measures.
• Priority on anti-COVID security protocols in public spaces.
• Pay attention to general health and immediately visit a health professional in case of symptoms of COVID-19.
• Immediate isolation of patients who present any symptoms.
• Follow the previously established indications in case of infection of this or any other of the variants.

Related Posts


Infected with monkeypox

After going through COVID-19, our society never imagined that it would take so little time before facing the next health emergency. It turns out that it arrived much earlier than we thought, and with more than 16,000 people infected in 75 countries in less than a year.

Even when it has not been as mediatic as COVID-19, Monkeypox already registers numbers that raise alerts from the World Health Organization. As a consequence, the Director General of this organization, Adhanom Ghebreyesus, declared a little less than a month ago that the disease is already classified as a global health emergency xnxx.



With the increase in the registration of cases worldwide and the scenario worsening day by day in Brazil, it was a matter of time before government and private organizations dedicated to health considered some countermeasures. Among them, the possibility of a massive vaccine began to appear.

However, the WHO denies the need for this measure. In recent statements, Rosamund Lewis, a specialist in this disease at the UN agency, recommended post-exposure vaccination as a countermeasure. However, the project is still in the coordination process for the release and distribution of the vaccines.

Currently, the recommendation for infected patients is partial or total isolation until recovery. Likewise, it is important that these patients check their temperature and possible symptoms between 9 and 12 days after infection.



Unlike COVID-19, we are fortunate to be facing a less silent and aggressive threat. Its characteristic hives and other physical symptoms make it much easier to spot. In addition, its clinical manifestation is usually mild.

Until now, Africa registers a 3.6% mortality according to the data registered in Europe. The most affected are usually children and young adults, as well as immunosuppressed people. Outside of this group, most patients have recovered within weeks.

The biggest complications are precisely skin infections, delusions and eye infections that decrease vision. Of this group, only about 6% have deaths. Mostly children with other health problems.




Being of mild clinical manifestation, the disease does not currently have a specific protocol or a defined treatment. Symptoms often simply disappear within 9-12 days without the need for treatment, implying that the human body naturally fights the disease and overcomes it without problems.

As key recommendations are:
• Monitor body temperature.
• Treat eye infections with standard treatment.
• Take care of skin infections by letting the area dry. If necessary, it can be covered with moist bandages.
• Avoid contact with the mouth or eyes.

Always remember that, for more information, you can consult the direct sources in the information portals of the WHO and other health organizations.




Related Posts



Access to Medicines: The Novartis Approach

The issue of “access to drugs” cannot be discussed in isolation from overall deficits in development policies, health policies and systems, and implementation processes. It is a complex issue that clearly includes the price of drugs but also goes far beyond that.

As a rule, the combination of appropriate development policy, effective health policy, best practices applied in the health system, a rational use of drugs, and adequately funded health services can handle most of the health problems in any country.

Although public health care saves millions of lives from premature death due to disease and injuries, several well-known problems remain:

The key role for the pharmaceutical industry is to discover, develop, produce, and market innovative products to prevent and cure diseases, to ease suffering, and to enhance the quality of life. Intellectual property rights are the lifeline of the research-based pharmaceutical industry and are vital to sustain continued R&D into new treatments.

In view of the substantial investments of time and capital to bring a drug to market, as well as the high risk of failure, the research efforts of the pharmaceutical industry are primarily focused on diseases with potential for an adequate return on investment.

New mechanisms are therefore urgently needed to foster research on diseases of poverty. A combination of market-based incentives (“push” and “pull” mechanisms to reduce the research and development costs and provide the necessary financial incentives) together with increased public funding and public private partnerships are called for.

Another option is to create a Consultative Group on International Health Research that would administer a global fund, financed by multilateral and bilateral donors as well as by NGOs, along the lines of the Consultative Group on International Agricultural Research.

The impact of patent protection on patients’ access to treatment in developing countries is often exaggerated: Although about 90% of the drugs on WHO’s model list of essential drugs are available off-patent, over a third of the world’s population still has no access to these drugs. As essential drugs for the management of HIV/AIDS and drug-resistant forms of TB are patent-protected, and therefore the exception to the rule, innovative and unorthodox solutions must be found to improve poor people’s access to these treatments.

The pharmaceutical industry is willing to work together to developing sustainable solutions. Individual companies such as Novartis will focus their efforts on improving access to treatments within their specific product portfolios.

The challenge therefore is to integrate the emerging global health system of intellectual property rights into a workable solution to make treatments available to poor people. TRIPS (Trade Related Aspects of Intellectual Property Rights) aims to strike such a balance by providing intellectual property protection and allowing countries the flexibility to ensure that treatments are available for the poor in situations of national emergencies, such as the HIV/AIDS pandemic.

Special price arrangements that permit the adaptation of prices for individual products and countries also provide a solution as they combine incentives for research with a wider distribution of benefits. Various safeguards will have to be in place to maintain the structure of these differentiated prices, such as control over trade to prevent re-exportation to high-priced markets, undertakings not to use the low prices as reference prices in developed markets, etc.

Despite greatly reduced prices for treatment such as HIV/AIDS and malaria, given the scale of the disease burden, providing treatment for all patients will continue to be beyond the means of governments in developing countries.

Substantially expanding access to essential medicines, including anti-retrovirals, will require additional domestic and international financing for the purchase of the drugs as well as a significant investment in building effective health and supply systems. Without the infrastructure and capacity building necessary to administer the HIV/AIDS drug regimens adequately and effectively, there is not only the danger of sub-optimal therapeutic success but also the risk of resistance to anti-retrovirals.

The Global Fund to Fight HIV/AIDS, TB and Malaria has been established to translate the unprecedented international and political attention into real commitments that will help improve access to the information, goods and services that people so urgently need. However the financial commitment to date of US$ 3.4 billion is significantly lower than the budget of US$ 7—10 billion required to launch a global response in order to stop and reverse the HIV/AIDS pandemic alone.

Novartis is committed to helping improve patients’ access to its treatments for diseases of poverty. Novartis has signed two Memorandums of Understanding with WHO-one to provide Free Treatment For All Leprosy Patients until the disease has been eliminated from every country, and the other to provide Coartem®, its oral fixed-combination anti-malarial product, at cost.

Novartis is committed to supporting pro bono research on diseases of poverty. It has established a research center in Singapore which will focus on developing new preventive and effective treatments for tuberculosis and dengue fever. The diseases affect two billion and 50 million people respectively mainly in developing countries. The Novartis Institute for Tropical Diseases is a result of an agreement between Novartis and the Singapore Economic Development Board (EDB) and involves an investment of US$ 122 million. The center could become closely associated with a Consultative Group on International Health Research (CGIHR) which is line with the recommendation of the WHO Commission on Macroeconomic and Health.

Novartis will donate 100,000 DOTS treatments (Directly Observed Treatment, Short-course) for tuberculosis every year for a five year period as its contribution to the Global Fund The Novartis donation will be channeled through the Global TB Drug Facility and thus take advantage of existing structures and expertise in order to improve patients access to TB diagnosis and treatment. The donation will be provided to some of the poorest developing countries where it can make a significant contribution to improve the TB situation.

Since 2002 Novartis is providing prevention, diagnosis, treatment, and counseling services for its employees and immediate family members (nucleus family) for HIV/AIDS, TB, and malaria in developing countries. The programme is being scaled to cover all employees working in countries with insufficient health insurance.

Novartis is working out the framework of a porno italiane programme, together with other partners, which aims at improving the access of poor communities in a sub-Saharan African country to comprehensive anti-malarial services (prevention and treatment) in a sustainable manner. Other partners could be the the Ministry of Health of the respective country, Swiss Development Cooperation, WHO, the World Bank, the Swiss Tropical Institute and Non-Governmental Organizations with competence in Access to Treatment issues.

Misallocation of public resources, in the sense of spending scarce resources on health interventions of low cost-effectiveness while underfunding critical and highly cost-effective health interventions;
inequity, in the sense that government spending intended to pay for basic health services for the poorest goes disproportionately to affluent segments of society; and
inefficiency, in the sense that health systems are often poorly structured and badly led, and their potential is squandered.